Results 171 to 180 of about 136,889 (307)

Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients

, 2002
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive ...
Erba F, Giannella S, Ceccherini Silberstein F, Bertoli A, Forbici F, Bellocchi MC, Antinori A, D’Arminio Monforte A, D’Arrigo R, Balotta C, Perno CF, Gori C, Trotta MP   +12 more
core  

AlphaFold2‐Guided Cyclic Peptide Stabilizer Design to Target Protein–Protein Interactions

Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 7, Page 1356-1370, July 2026.
ABSTRACT The control and modulation of protein–protein interactions (PPIs) is of central importance for the majority of biological processes and most biomedical applications. Stabilization of PPIs, besides inhibition, is of growing pharmaceutical interest.
Niklas Halbwedl, Martin Zacharias
wiley   +1 more source

Designing Potent HIV‑1 Protease Inhibitors Using Machine Learning and QSAR Approaches. [PDF]

ACS Omega
Ali S, Dwi Putra I, Chuntakaruk H, Wolschann P, Maitarad P, Rungrotmongkol T, Hannongbua S.   +6 more
europepmc   +1 more source

Retracted: Effect of HIV-1 Protease Inhibitor on IL-18 and IL-1β in Rats with Insulinoma. [PDF]

Dis Markers, 2023
Markers D.
europepmc   +1 more source

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 74-88, July 2026.
Using UK Biobank proteomic data, we identified a five‐protein score reflecting hepatic stellate cell activation and hepatocellular injury that predicts major adverse liver outcomes and clinically significant fibrosis, with consistent performance validated in two independent cohorts (patients with HIV and alpha1‐antitrypsin deficiency).
Sriram Balasubramani, Katharina Remih, Anna Sophie Karl, Julia Alexandra Borchert, Christina Schrader, Malin Fromme, Can Kayatekin, Bailin Zhang, Mikhail Levit, Pavithra Krishnaswami, Louise E. van Eekeren, Leo A. B. Joosten, Twan Otten, Petra Tomanová, Pavel Strnad   +14 more
wiley   +1 more source

Residue-Level Affinity Decomposition via Quantum Electron Density: A Multivariable Framework Applied to HIV-1 Protease Inhibitors. [PDF]

J Phys Chem B
Gutiérrez-Flores J, Padilla-Bernal G, Sánchez-Juárez C, Méndez-Orduña DM, Serrano Medina J, García-Gutiérrez P, Zubillaga RA, Vargas R.   +7 more
europepmc   +1 more source

Inhibition of HIV-1 Protease by a Boronic Acid with High Oxidative Stability. [PDF]

ACS Med Chem Lett, 2023
Graham BJ, Windsor IW, Raines RT.
europepmc   +1 more source

HIV protease inhibitors: a review of molecular selectivity and toxicity

, 2015
Zhengtong Lv,* Yuan Chu,* Yong Wang Department of Immunology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China *Both authors contributed equally to this work ...
Lv Z, Chu Y, Wang Y
core  

Glycolytic metabolism of CD8+ T‐cells affects susceptibility to human leukocyte antigen‐mediated abacavir‐induced hypersensitivity

British Journal of Pharmacology, Volume 183, Issue 13, Page 3743-3761, July 2026.
Abstract Background and Purpose Drug hypersensitivity reactions (DHRs) associated with a specific human leukocyte antigen (HLA) allotype do not manifest uniformly in all individuals within an HLA model population. This scenario highlights the complexity of predicting drug hypersensitivity reaction risk without considering additional factors ...
Takeshi Susukida, Yuchen Sun, Noriaki Arakawa, Takuya Hirao, Tadahaya Mizuno, Shigeki Aoki, Kousei Ito, Yoshihiro Hayakawa   +7 more
wiley   +1 more source

Highly Potent Phosphinic HIV‑1 Protease Inhibitors: Synthesis, In Vitro Evaluation, and Docking Studies. [PDF]

ACS Omega
Hayat K, Qiu D, Wang Y, Imbenzi PS, Khan FI, Matziari M.   +5 more
europepmc   +1 more source